Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
News|Articles|June 2, 2024
Psychedelics Recommendations Poll
Author(s)Psychiatric Times Editors
Answer a quick question on psychedelics!
Advertisement
If approved by the FDA, would you recommend psychedelics to your patients as an option?
Advertisement
Related to this article
Athletes can feel the relief a substance gives them long before they can see what it costs. A composite case of cannabis use in a track athlete shows how to assess both.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Psych Consult: TSH Testing in New-Onset Depression. An Endocrinologist’s Guidance for Psychiatrists
2
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
3
Adjustment Disorder Is Hiding in Plain Sight
4
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
5